Education
About Us
Working with TipRanks
Follow Us
Replimune Group (REPL)
:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.92 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)688.14K
Market Cap
$804.80M
Enterprise Value$505.19M
Total Cash (Recent Filing)$172.25M
Total Debt (Recent Filing)$30.08M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 15, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding77,014,780
10 Day Avg. Volume804,614
30 Day Avg. Volume688,137
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-190.28
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$22.14Price Target Upside111.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRP1 + Opdivo achieved an objective response rate (ORR) of 33.6%, which is significantly higher than what would be expected with an anti-PD1 agent alone in an anti-PD1-refractory melanoma population.
Financial PositionREPL guides to sufficient cash runway to fund operations into 4Q26, accounting for the costs associated with scaling up for the potential commercialization of RP1 in skin cancers.
Regulatory ApprovalsThe FDA granted breakthrough therapy designation for RP1 + nivolumab in anti-PD-1-failed melanoma.
Bears Say
Operational RisksThe ongoing ramp-up in manufacturing in preparation for the potential launch of RP1 may present operational challenges.
Regulatory ChallengesThe BLA came with Priority Review status and a PDUFA action date of July 22, 2025, which has significantly de-risked RP1's regulatory pathway.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $4.92 and its highest was $17.00 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $804.80M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is May 15, 2025 which is in 47 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Feb 06, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.706 by -$0.084.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate is -0.75.
How many shares outstanding does Replimune Group have?
Replimune Group has 77,014,780 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.706. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
---
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (111.87% Upside)
$22.14 (111.87% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 37.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $134.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.66%
12-Months-Change
Fundamentals
Return on Equity
-50.50%
Trailing 12-Months
Asset Growth
13.27%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
---
REPL Stock 12 Month Forecast
Average Price Target
$22.14
▲(111.87% Upside)
Technical Analysis
Best Analysts Covering REPL
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+8.04%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +8.04% per trade.
---